Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 19/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20242658 | 0.90 | RIPK1 (0.75) | RIPK1ALDH1A1 | |
| SCHEMBL17881946 | 0.88 | RIPK1 (0.81) | RIPK1 | |
| SCHEMBL18255210 | 0.88 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL20254439 | 0.86 | RIPK1 (0.77) | RIPK1 | |
| SCHEMBL18248356 | 0.85 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL18248359 | 0.85 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL18248275 | 0.85 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL20254435 | 0.83 | RIPK1 (0.56) | RIPK1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL20138360 | 0.83 | RIPK1 (0.88) | RIPK1 | |
| SCHEMBL20254434 | 0.82 | RIPK1 (0.63) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12180211-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2024-12-31 | — | — | US | disclosed |
| CN-110383066-B | Compounds, compositions and methods | 戴纳立制药公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-3552017-B1 | COMPOUNDS USEFUL AS RIPK1 INHIBITORS | DENALI THERAPEUTICS INC (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20210332058-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2021-10-28 | — | — | US | disclosed |
| US-20210332058-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2021-10-28 | — | — | US | disclosed |
| US-11072618-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-11072618-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2021-07-27 | — | — | US | disclosed |
| EP-3552017-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190300537-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2019-10-03 | — | — | US | disclosed |
| US-20190300537-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2019-10-03 | — | — | US | disclosed |
| WO-2018107060-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018107060-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2018-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12180211-B2 | Compounds, compositions and methods | BAX, CASP3, CASP8 | RIPK1 263/4885ALDH1A1 3491/4885 |
| US-11072618-B2 | Compounds, compositions and methods | BAX, CASP3, CASP8 | RIPK1 263/4885ALDH1A1 3491/4885 |
| US-20210332058-A1 | Compounds, Compositions and Methods | BAX, CASP3, CASP8 | RIPK1 263/4885ALDH1A1 3491/4885 |
| US-20190300537-A1 | Compounds, Compositions and Methods | BAX, CASP3, CASP8 | RIPK1 263/4885ALDH1A1 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.